ERBB2 and triple-negative breast carcinoma: In this study, APP expression was highly expressed in non-luminal breast cancer, which demonstrated human epidermal growth factor receptor 2–overexpressed (HER2-OE, 39.3%) and triple-negative breast cancer (TNBC, 38.2%), as compared with 8% in luminal A cancer.